Bram De Wilde
Overview
Explore the profile of Bram De Wilde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1883
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen T, van Gelder J, van de Ven B, Amitonov S, De Wilde B, Ruiz Euler H, et al.
Nature
. 2025 Mar;
PMID: 40069578
No abstract available.
2.
Dubois S, Ogawa C, Moreno L, Mosse Y, Fischer M, Ryan A, et al.
Cancer
. 2025 Feb;
131(4):e35751.
PMID: 39932800
Background: This study evaluated the safety, pharmacokinetics, and antitumor activity of LY3295668 erbumine as monotherapy and combination therapy in children with relapsed/refractory neuroblastoma. Methods: Patients aged 2-21 years who had ...
3.
Lamoureux A, Fisher M, Lemelle L, Pfaff E, Amir-Yazdani P, Kramm C, et al.
Clin Cancer Res
. 2024 Dec;
31(3):561-572.
PMID: 39625867
Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design:...
4.
Ma J, Zhang Y, Gu S, Ge C, Mae S, Young A, et al.
Lancet Digit Health
. 2024 Oct;
6(11):e815-e826.
PMID: 39455194
Deep learning has shown great potential to automate abdominal organ segmentation and quantification. However, most existing algorithms rely on expert annotations and do not have comprehensive evaluations in real-world multinational...
5.
Bonine N, Zanzani V, Van Hemelryk A, Vanneste B, Zwicker C, Thone T, et al.
Cell Rep
. 2024 Oct;
43(10):114804.
PMID: 39368085
Neuroblastoma, a rare embryonic tumor arising from neural crest development, is responsible for 15% of pediatric cancer-related deaths. Recently, several single-cell transcriptome studies were performed on neuroblastoma patient samples to...
6.
Cornelli L, Van Paemel R, Ferro Dos Santos M, Roelandt S, Willems L, Vandersteene J, et al.
Clin Epigenetics
. 2024 Jul;
16(1):87.
PMID: 38970137
Pediatric central nervous system tumors remain challenging to diagnose. Imaging approaches do not provide sufficient detail to discriminate between different tumor types, while the histopathological examination of tumor tissue shows...
7.
De Wilde J, Van Paemel R, De Koker A, Roelandt S, Van de Velde S, Callewaert N, et al.
Lab Invest
. 2024 Jun;
104(8):102091.
PMID: 38830578
Currently, we cannot provide a conclusive diagnosis for 3% to 5% of people who are confronted with cancer. These patients have cancer of unknown primary (CUP), ie, a metastasized cancer...
8.
Moreno L, Weston R, Owens C, Valteau-Couanet D, Gambart M, Castel V, et al.
J Clin Oncol
. 2024 Jan;
42(10):1135-1145.
PMID: 38190578
Purpose: Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens and the addition of the antiangiogenic...
9.
Gelineau N, van Barneveld A, Samim A, Van Zogchel L, Lak N, Tas M, et al.
Front Oncol
. 2023 Sep;
13:1209150.
PMID: 37664065
Background And Aims: Solid tumors account for about 30% of all pediatric cancers. The diagnosis is typically based on histological and molecular analysis of a primary tumor biopsy. Liquid biopsies...
10.
Moreno L, Teira P, Croop J, Gerber N, Andre N, Aerts I, et al.
Front Pediatr
. 2023 Jun;
11:1183295.
PMID: 37292376
Background: The survival rates for pediatric patients with relapsed and refractory tumors are poor. Successful treatment strategies are currently lacking and there remains an unmet need for novel therapies for...